All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Which R/R AML subgroups would benefit from enasidenib treatment?

During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, Which relapsed/refractory AML subgroups would benefit from enasidenib treatment?

Which R/R AML subgroups would benefit from enasidenib treatment?

DiNardo begins by explaining the importance of an IDH2 mutation for the efficacy of this targeted inhibitor. She then reports on promising results from the enasidenib versus conventional care regimens trial.

Share: